Xenon Pharmaceuticals Inc. · NASDAQ:XENE

Xenon Pharmaceuticals — Epilepsy Foundation 2018 Pipeline Conference

10 slides from Xenon Pharmaceuticals's conference presentation, February 2018

  1. Slide 1: XEN1101, a Novel Modulator of Kv7.2/3 for the Treatment of Epilepsy

    XEN1101, a Novel Modulator of Kv7.2/3 for the Treatment of Epilepsy Y Paul Goldberg MB ChB, PhD, FRCPC SVP, Clinical Development

  2. Slide 2: Forward Looking Statement/Safe Harbor

    Forward Looking Statement/Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from

  3. Slide 3: XEN1101: Improved 2nd Generation KV7.2 Opener

    XEN1101: Improved 2nd Generation KV7.2 Opener  Human genetic validation of KCNQ2 target • De novo dominant negative missense mutations cause EIEE7  Good pharmacological validation as ezogabine was approved in 2011 for treatment resistant epilepsy  Potential for best-in-class KV7.2 opener • XEN110

  4. Slide 4: XEN1101: Improved 2nd Generation KV7.2 Opener

    XEN1101: Improved 2nd Generation KV7.2 Opener  No potential to form colored dimers  ~20-fold more potent for KV7.2/7.3 heterotetramers over ezogabine  ~2-3-fold more selective over KV7.4 and KV7.5  No activity on KV7.1, hERG, GABA  Greater potency than ezogabine and other AEDs in multiple anima

  5. Slide 5: XEN1101: Potent Efficacy in Animal Models

    XEN1101: Potent Efficacy in Animal Models  More potent than ezogabine and other AEDs in animal models Mice IP Mice IP Mice IP Mice IP Mice IP Mice IP MES Metrazol Picrotoxin Bicuculline 6 Hz, 32 mA 6 Hz, 44 mA ED50 (mg/kg) ED50 (mg/kg) ED50 (mg/kg) ED50 (mg/kg) ED50 (mg/kg) ED50 (mg/kg) Ezogabine 2

  6. Slide 6: XEN1101 Improved Therapeutic Index Versus Ezogabine

    XEN1101 Improved Therapeutic Index Versus Ezogabine 6

  7. Slide 7: PK in NHP Predicts Once Daily Dosing in Humans

    PK in NHP Predicts Once Daily Dosing in Humans • Mean plasma concentrations in NHP after repeat oral dosing • Low peak to trough ratio • Supports QD dosing 7

  8. Slide 8: XEN1101 Development Overview

    XEN1101 Development Overview  Phase 1: Adaptive integrated design underway, readout expected mid 2018  SAD/MAD study with pilot TMS (transcranial magnetic stimulation)  TMS cross-over study • Dosing following selection of dose from SAD/MAD/pilot TMS  Chronic GLP toxicology studies in rat and NHP

  9. Slide 9: XEN1101 Summary

    XEN1101 Summary  Best/only-in-class KV7.2/3 modulator  Highly genetically and clinically validated mechanism  Highly efficacious in a broad range of epilepsy animal models  Excellent oral PK in animal models predicts once daily dosing  Expect lower Cmax related CNS AEs compared to ezogabine  N

  10. Slide 10: Acknowledgements

    Acknowledgements • 1st Order Pharmaceuticals Xenon Pharmaceuticals • Chris Crean • Greg Beatch • Kings College Hospital • Ying Man • Jay Cadieux • Richmond Pharmacology • Rostam Namdari Ltd. • Heather Kato • Catherine Leung • Paul Bichler • Robin Sherrington • Alix Helper • Simon Pimstone Epilepsy F

Xenon Pharmaceuticals — Epilepsy Foundation 2018 Pipeline Conference on 6ix